FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025677531> ?p ?o ?g. }

• W2025677531 endingPage "481" @default.
• W2025677531 startingPage "477" @default.
• W2025677531 abstract "The use of 131I treatment in nodular toxic goiter is widely accepted. In this article, we describe transition of nodular toxic goiter into an autoimmune toxic goiter with development of thyrotropin receptor antibodies (TRAb) as a side effect of 131I treatment. In this retrospective study, 149 patients with nodular toxic goiter (100 with multinodular goiter, 49 with a solitary autonomously functioning toxic nodule) were studied. Of these 149 patients 100 became permanently euthryoid after 1 dose of 131I, and due to persistent hyperthyroidism, 32 patients needed 2-5 doses to became euthyroid. After becoming euthyroid, none of these 132 patients had relapse of hyperthyroidism in the follow-up period. Based on evaluation of the thyroid hormone variables, 17 of 149 patients had a distinctly different pattern in the changes in thyroid hormones. They developed an increase in FT4I 3-6 months posttreatment after an initial fall in FT4I. Twelve of these 17 patients were treated with antithyroid drugs before the initial 131I dose. On samples of frozen sera (-20°C) anti-thyroid peroxidase (TPO) and TRAb were followed for 6 months after 131I treatment in these 17 patients. A similar follow-up was done in 20 patients (10 with and 10 without antithyroid drug pretreatment), randomly selected from the patients who did not relapse. In the remaining 112 patients, anti-TPO and TRAb levels were measured only before the 131I treatment. Of the 17 patients with relapse, 6 developed TRAb concomitant with recurrence of hyperthyroidism (4% of the study group). In 5 of the 17 patients TRAb values remained absent throughout the follow-up period. The remaining 6 patients had elevated TRAb values before 131I treatment. Among the 132 patients who did not relapse, an additional 7 cases with presence of TRAb were found. A total of 9% of the study group was found to have TRAb before 131I pretreatment. Anti-TPO was found in 20 of 149 patients (13%) before 131I treatment. Complications, either hypothyroidism or TRAb-associated hyperthyroidism, were seen in 8 of 20 patients (40%) with anti-TPO before 131I treatment, compared to 9 of 129 (7%) without (p < 0.005). In conclusion, TRAb and a Graves' like hyperthyroidism can be triggered by 131I treatment in patients with nodular toxic goiter. The presence of anti-TPO seem to be a marker of an increased risk of development of TRAb-associated hyperthyroidism as well as hypothyroidism, but both side effects can be seen despite the absence of anti-TPO autoantibodies." @default.
• W2025677531 created "2016-06-24" @default.
• W2025677531 creator A5000610455 @default.
• W2025677531 creator A5037884692 @default.
• W2025677531 creator A5039528393 @default.
• W2025677531 creator A5058224154 @default.
• W2025677531 creator A5072362865 @default.
• W2025677531 date "1999-05-01" @default.
• W2025677531 modified "2023-10-18" @default.
• W2025677531 title "Transition of Nodular Toxic Goiter to Autoimmune Hyperthyroidism Triggered by 131I Therapy" @default.
• W2025677531 cites W1983680839 @default.
• W2025677531 cites W1986277703 @default.
• W2025677531 cites W1996499579 @default.
• W2025677531 cites W1998680549 @default.
• W2025677531 cites W1998721237 @default.
• W2025677531 cites W2014820821 @default.
• W2025677531 cites W2022718216 @default.
• W2025677531 cites W2032359156 @default.
• W2025677531 cites W2037236834 @default.
• W2025677531 cites W2084570366 @default.
• W2025677531 cites W2089162443 @default.
• W2025677531 cites W2127748061 @default.
• W2025677531 cites W2158470744 @default.
• W2025677531 cites W2171587699 @default.
• W2025677531 cites W4251686044 @default.
• W2025677531 cites W4252497646 @default.
• W2025677531 doi "https://doi.org/10.1089/thy.1999.9.477" @default.
• W2025677531 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10365679" @default.
• W2025677531 hasPublicationYear "1999" @default.
• W2025677531 type Work @default.
• W2025677531 sameAs 2025677531 @default.
• W2025677531 citedByCount "76" @default.
• W2025677531 countsByYear W20256775312012 @default.
• W2025677531 countsByYear W20256775312014 @default.
• W2025677531 countsByYear W20256775312015 @default.
• W2025677531 countsByYear W20256775312016 @default.
• W2025677531 countsByYear W20256775312017 @default.
• W2025677531 countsByYear W20256775312018 @default.
• W2025677531 countsByYear W20256775312019 @default.
• W2025677531 countsByYear W20256775312020 @default.
• W2025677531 countsByYear W20256775312021 @default.
• W2025677531 countsByYear W20256775312022 @default.
• W2025677531 countsByYear W20256775312023 @default.
• W2025677531 crossrefType "journal-article" @default.
• W2025677531 hasAuthorship W2025677531A5000610455 @default.
• W2025677531 hasAuthorship W2025677531A5037884692 @default.
• W2025677531 hasAuthorship W2025677531A5039528393 @default.
• W2025677531 hasAuthorship W2025677531A5058224154 @default.
• W2025677531 hasAuthorship W2025677531A5072362865 @default.
• W2025677531 hasConcept C126322002 @default.
• W2025677531 hasConcept C134018914 @default.
• W2025677531 hasConcept C2776254400 @default.
• W2025677531 hasConcept C2776652619 @default.
• W2025677531 hasConcept C2777195454 @default.
• W2025677531 hasConcept C2778696486 @default.
• W2025677531 hasConcept C2778707442 @default.
• W2025677531 hasConcept C2779384505 @default.
• W2025677531 hasConcept C526584372 @default.
• W2025677531 hasConcept C71315377 @default.
• W2025677531 hasConcept C71924100 @default.
• W2025677531 hasConcept C90924648 @default.
• W2025677531 hasConceptScore W2025677531C126322002 @default.
• W2025677531 hasConceptScore W2025677531C134018914 @default.
• W2025677531 hasConceptScore W2025677531C2776254400 @default.
• W2025677531 hasConceptScore W2025677531C2776652619 @default.
• W2025677531 hasConceptScore W2025677531C2777195454 @default.
• W2025677531 hasConceptScore W2025677531C2778696486 @default.
• W2025677531 hasConceptScore W2025677531C2778707442 @default.
• W2025677531 hasConceptScore W2025677531C2779384505 @default.
• W2025677531 hasConceptScore W2025677531C526584372 @default.
• W2025677531 hasConceptScore W2025677531C71315377 @default.
• W2025677531 hasConceptScore W2025677531C71924100 @default.
• W2025677531 hasConceptScore W2025677531C90924648 @default.
• W2025677531 hasIssue "5" @default.
• W2025677531 hasLocation W20256775311 @default.
• W2025677531 hasLocation W20256775312 @default.
• W2025677531 hasOpenAccess W2025677531 @default.
• W2025677531 hasPrimaryLocation W20256775311 @default.
• W2025677531 hasRelatedWork W100799464 @default.
• W2025677531 hasRelatedWork W1987257907 @default.
• W2025677531 hasRelatedWork W2351921826 @default.
• W2025677531 hasRelatedWork W2358633025 @default.
• W2025677531 hasRelatedWork W2392107066 @default.
• W2025677531 hasRelatedWork W2392543696 @default.
• W2025677531 hasRelatedWork W2589376621 @default.
• W2025677531 hasRelatedWork W3049752579 @default.
• W2025677531 hasRelatedWork W3208354384 @default.
• W2025677531 hasRelatedWork W3210336984 @default.
• W2025677531 hasVolume "9" @default.
• W2025677531 isParatext "false" @default.
• W2025677531 isRetracted "false" @default.
• W2025677531 magId "2025677531" @default.
• W2025677531 workType "article" @default.